Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Comment by Guavaon Feb 17, 2012 7:29am

331 Views

Post# 19547962

RE: RE: RE: RE: GPD hold

Vendy, I am completely agreed with your comments.

GPD has promised to the market three technical reports since summer 2011 (Grew Creek, Clear Creek, and Brewery Creek projects), and we have not seen any yet. They drilled at the Eureka and the Antimony projects, and they have not released any drill results. The Brewery Creek technical report was supposed to be public at the Cambridge house last January in Vancouver. The last two GPD NRs said that will be released at the end of January. I have just read that will be released in April now.

I am still concerned why Alexco run out of Brewery Creek Project. Any producing mining company wants an asset like it. Then is something else that we do not know yet. I hope that it will be positive news.

Bullboard Posts

Options trading in a volatile macro environment